Press Release: Nastech Pharmaceutical Company To Get $42.9M In 3.25M Stake Offer

Nastech Pharmaceutical Company To Get $42.9 Million In 3.25 Million Stake Offer BOTHELL, Wash., Jan. 18 -- Nastech Pharmaceutical Company Inc. today announced the pricing of an underwritten public offering of 3.25 million shares of its common stock at an estimated total public offering price of up to approximately $42.9 million. The offering is being made pursuant to a shelf registration that became effective on November 29, 2006. All of the shares are being sold by Nastech. UBS Investment Bank acted as sole bookrunner for the offering. The Company has granted the underwriter an option to purchase up to an additional 487,500 shares to cover over-allotments in the offering, if any. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. A prospectus supplement and the accompanying base prospectus relating to these securities will be filed with the Securities and Exchange Commission (the "SEC") and will be available on the SEC's website at http://www.sec.gov. This offering of shares of common stock may be made only by means of the prospectus supplement and accompanying base prospectus, a copy of which can be obtained upon request in writing to UBS Securities LLC, 299 Park Avenue, New York, NY 10171, Attn: Equity Syndicate Desk. About Nastech Nastech is a pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, diabetes, obesity, respiratory diseases and inflammatory conditions. Contacts: Nastech Pharmaceutical Company Inc. Ed Bell Senior Investor Relations Manager (425) 908-3639 [email protected] Noonan Russo Matthew Haines (Investors/Media) (212) 845-4235 Nastech Pharmaceutical Company Inc. CONTACT: Ed Bell, Senior Investor Relations Manager of NastechPharmaceutical Company Inc., +1-425-908-3639, [email protected]; orInvestors/Media: Matthew Haines of Noonan Russo, +1-212-845-4235

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.